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The optical molecular imaging of inflammation is an emerging strategy for interventional
medicine and diagnostics. The host’s inflammatory response and adaptation to acute
and chronic diseases provides unique signatures that have the potential to guide
interventions. Thus, there are emerging a suite of molecular imaging and sensing
approaches for a variety of targets in this area. This review will focus on two key
cellular orchestrators that dominate this area, neutrophils and macrophages, with recent
developments in molecular probes and approaches discussed.
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INTRODUCTION
Recent developments in optical molecular imaging are enabling the identification and evaluation
of inflammatory cells such as macrophages and neutrophils in a variety of imaging scenarios. This
is important as these leukocytes are an important part of host defense and immune homeostasis.
Their pivotal roles as professional phagocytes in acute and chronic inflammatory disease may allow
their use as versatile interventional biomarkers and as such fluorescent imaging of these cells has
the potential to advance disease treatment andmanagement, by producing sub-cellular information
in real-time.
Intrinsic tissue autofluorescence adds further value when the structures of extracellular matrix
or metabolic activities are of interest. The predominant modality of fluorescence intensity
measurements, coupled with recent technological developments such as label-free non-linear
optical images and Raman analyses (1, 2), have opened up the possibility of giving the surgeon
functional images of the surgical site in real time. Furthermore, exciting developments are resulting
from the integration of cell classification andmachine learning techniques, allowing deeper analysis
of the richness of imaging datasets.
Macroscopic widefield open fluorescence systems and high-resolution endomicroscopy are the
predominant systems that have been used clinically to detect optical molecular tracers. The recent
advances in imaging technology mean that fluorescence guided surgery is becoming a reality for
cancer resection (3). Complete tumor removal is crucial for patient outcomes, but difficult to ensure
by conventional microscopy as visual characteristics and palpitation are inadequate to determine
tumor-free margin. With fluorescence systems, surgeons have the future ability to assess the extent
of tumor excision and local metastases in real-time using a fluorescent label that “lights-up” the
tumor and hence delineates its margins. Optical endomicroscopy (OEM) enables optical imaging at
high resolution typically via a bundle of optical fibers (although rapidly being replaced by chip-on-
tip technologies) to enable imaging with microscopic resolution, with the added ability to explore
within a variety of cavities. Recently fiber-bundle endomicroscopy has been used in the lung to
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assess alveolar structure in emphysema, neoplastic changes in
epithelial cells and real-time in vivo detection of bacteria (4–6).
As well as in the GI tract, where it has been used to detect changes
associated with squamous cell carcinoma and colorectal polyps
(7). There are a range of OEM platforms, spanning clinical use
and developmental systems (6, 8), although standardization is
necessary to generate meaningful diagnostic data (9).
Alongside the devices that enable real-time fluorescence
imaging capability, optical molecular probes are required that
provide contrast and are suitable for use in vivo. Although
extensive libraries of optical agents for many targets have been
developed (10, 11), none have been licensed for routine clinical
use. This review will focus on fluorescent molecular probes for
inflammatory cells, in particular neutrophils and macrophages.
Recent agents allow the identification of these cells, as well
as providing information on dynamic cellular processes such
as enzymatic activity, redox processes, and phagocytic ability;
processes that impact pathophysiology. Overall, inflammatory
cell imaging creates an ideal paradigm for patient-specific disease
monitoring and intervention (Table 1). Recent advances in the
fluorescent and Raman imaging are enabling macrophage and
neutrophil burden and activity to be described non-invasively
and dynamically with tissue-level resolution.
NEUTROPHILS AS BIOMARKERS
As cells that migrate to diseased tissues and accumulate, both
over the course of a disease and due to chemotactic stimuli,
neutrophils can provide meaningful prognostic data just by
their enumeration. Neutrophil counts have long been used to
stratify patients by scoring disease, for example in ulcerative
colitis (25). Several large patient studies and systematic reviews
show the neutrophil to lymphocyte ratio is useful in staging
inflammatory bowel disease (IBD) and numerous solid tumors
(13, 14), as well as predicting cardiovascular disease, diabetic
neuropathy, sepsis-induced acute kidney injury, glaucoma and
bacteremia (15–19, 26). Simple neutrophil enumeration may
even resolve the controversial question of when to intervene
in carotid artery disease (27). Using explanted human tissues
Ionita et al. evidenced correlations between neutrophil count and
several critical factors in atherosclerotic plaque stability (28).
Of course, more sophisticated insights can be drawn
from considering the viability status of neutrophils and
quantifying neutrophil extracellular traps (NETs) independently
of neutrophils in altered activation states. The accumulation
of neutrophils on the ocular surface in dry-eye disease (DED)
is thought to result in pathological NET formation (29). With
the recent success of a phase I/II study evaluating DNase
treatment for DED, NET burden is becoming an important
clinical parameter in this disease (30). Also, neutrophil nuclei
Abbreviations: DiD, A lipophilic carbocyanine dye; FAM, Carboxyfluorescein;
FITC, Fluorescein isothiocyanate; FLIM, Fluorescence lifetime imaging
microscopy; FRET, Förster resonant energy transfer; FR, Folate receptor;
HNE/NE, (Human) neutrophil elastase; IBD, Inflammatory bowel disease; MMP,
Matrix metalloproteinase; MMR, Macrophage mannose receptor; NIR, Near
infrared; OEM, Optical endomicroscopy; PET, Positron emission tomography;
TPEM, Two-photon endomicroscopy; UC, Ulcerative colitis.
TABLE 1 | Evidence for the role of neutrophils and macrophages as biomarkers in
various diseases.
Cell Information Disease References
Neutrophil Disease stage Gastrointestinal tumors (12)
Solid tumors (13)
Inflammatory bowel disease (14)
Disease onset Bacteremia (15)
Sepsis-induced acute
kidney injury
(16)
Critical event Cardiovascular (17)
Diabetic neuropathy (18)
Chronic obstructive
pulmonary disease
(19)
Pesticide poisoning (20)
Macrophage Disease stage Solid tumors (21)
Sentinel lymph node
metastasis (breast cancer)
(22)
Rheumatoid arthritis (23)
Liver fibrosis (24)
Data referenced to meta-analyses or patient studies in the literature.
undergo morphological changes in DED that can assist the
detection of DED-related hyperosmolarity (31). Due to the
abundance of human neutrophil elastase (HNE) in NETs (32)
and this enzyme’s stimulatory role in mucin production (33),
HNE may allow diagnostic disease monitoring in DED. Beyond
the conjunctiva, neutrophil infiltration is inversely correlated
with neuroprotection D1 and their pro-inflammatory activity has
clear implications in retinal vascular and neural degeneration
(34). Tumor associated neutrophils (TANs) play a wide array
of roles and their investigation can reveal where they act in
opposition. For example, in early stage lung cancer TANs were
shown to help limit disease progression however animal models
have elucidated several pro-tumoral mechanisms (35, 36). Some
of the heterogeneity measured may come from relying on
the expression of TAN markers which can vary in different
tumor microenvironments and no suitable marker exists for
distinguishing between the N1 and N2 phenotypes (37).
Another layer of insight may be accessible via measurement
of neutrophil activity, as studies of patients with inflammatory
bowel disease have demonstrated. Patient studies found changes
in fecal lactoferrin, calprotectin and the protease HNE were
significantly correlated with endoscopy and could be used to
distinguish between mild disease, mucosal healing and clinical
remission, and even predict flare onset (38). HNE is further
implicated in IBD treatment by cleaving therapeutic monoclonal
antibodies Infliximab, Adalumimab, Vedolizumab (39). The
varied and clear benefits of such simple and direct analyses
highlight the precision of the inflammatory response and the
diagnostic potential of optical probes for neutrophil imaging.
NEUTROPHIL IMAGING PROBES
Neutrophils are the first leukocytes to be recruited to an
inflammatory site. Their capacities to respond en masse and
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TABLE 2 | Overview of optical probes for imaging neutrophils.
Target Molecule class Optical modality Models References
Serprocidins Quenched dendrimeric probe Fluorescence Human cells ex vivo (40)
HNE Quenched probe Fluorescence Mouse (41)
Quenched dendrimeric probe Fluorescence Sheep, human (42)
FPR1 Peptide Fluorescence Human (43)
Radioactive nanoparticle Dual PET/MRI Mouse (44)
Nucleus Label-free Raman Human cells ex vivo (45)
Label-free 2-photon FLIM Human (46)
rapidly underscore their potential as biomarkers capable of
producing large readouts in short time-frames—properties that
are particularly desirable for surgical guidance. The relatively
short neutrophil half-life acts to limit any off-target consequences
of labeling to days or hours, whilst the persistence of
the neutrophilic influx in inflamed tissues makes neutrophil
readouts useful over the entire disease monitoring period,
irrespective of its duration. Overall, neutrophil imaging creates
an ideal paradigm for patient-specific disease monitoring and
intervention. Recent advances in the fluorescent and Raman
spectroscopic modes of optical imaging are, for the first time,
enabling neutrophil burden and activity to be described non-
invasively and dynamically with tissue-level resolution (Table 2).
Proteases
Human neutrophil elastase (HNE) is a serprocidin stored
at millimolar concentrations in the azurophil granules of
neutrophils (47). Although HNE is chiefly a microbicidal
protease, its broad substrate specificity allows neutrophils to
use it intracellularly, extracellularly and in membrane-bound
form for a variety of purposes. Phagocytosis, extravasation
(48), extracellular matrix remodeling (49–51), cell-signaling
(52), mucus production (53), mucociliary function, (54),
and NETosis (55) all have roles for HNE and a host of
further interactions give the enzyme utility for other cell-types
including monocytes, endothelial, and adenocarcinoma cells.
When released by activated neutrophils HNE can be used to
destroy pathogens and promote neovascularization as part of
tissue repair, however sustained HNE release contributes to
the pathophysiological sequalae of acute respiratory distress
syndrome, lung adenocarcinoma, atherosclerosis and other
chronic inflammatory diseases.
Craven et al. recently reported a probe that revealed
neutrophil activation. This was designed to detect the serine
proteases (serprocidins) using a pan-serprocidin substrate. A
tribranched probe was developed which maintains an optically
super-silent ground state with a methyl red and fluorescein FRET
pair on each of its three branches (Figure 1A) (40). The structure
facilitates internalization by activated neutrophils and once in the
phagolysosome, active serprocidins cleave the peptide sequences
to remove the methyl red quenchers and generate a large
fold increase in fluorescence (Figure 1B). The probe generates
bright intracellular puncta, in human neutrophils, within seconds
of activation with pharmacological stimulus or bacterial co-
incubation. By adding the probe to whole blood in a simple, no-
wash, no-lyse, flow cytometric assay, activated neutrophils could
be profiled (Figure 1C). Combining rapid signal generation and
detailed cell-type specific analysis situates this pan-serprocidin
probe as a promising patient-stratification biomarker for several
chronic inflammatory diseases.
The neutrophil elastase probe NE680 is a near-infrared multi-
branched probe which is sensitive to cleavage by murine NE and
HNE, amongst others (Figure 2) (41). It consists of a peptide
sequence (PMAVVQSVP) flanked by NIR fluorophores and
conjugated to a polylysine dendrimer, which lengthens its plasma
and tissue half-lives and results in internal quenching. Upon
cleavage by proteases, NIR fluorescence emission is generated.
NE680’s quantification of NE activity was demonstrated by
incubating lung sections, from LPS/fMLF challenged mice,
in increasing doses of the NE-specific inhibitor, sivelestat
(Figures 2C,D). Non-invasive, quantitative NE imaging was
demonstrated using fluorescence molecular tomography (41).
Wang et al. demonstrated a similar dose dependent reduction
in NIR fluorescence of NE680 could be achieved under
more physiologically relevant conditions, using recombinant
alpha 1-antiproteinase (a1PI) instead of sivelestat (56). Further
studies using NE680 have revealed roles for NE in promoting
neutrophil accumulation in atherosclerotic plaques, insulin
resistance and arthritic pain, in murine models (57–59).
Although NE680 cleavage by HNE has been demonstrated in
vitro, structural differences between the murine and human
NE active sites and functional differences between murine and
human neutrophils mean the clinical utility of NE680 has yet to
be demonstrated.
Although a wealth of neutrophil probes have not reached
in vivo studies, exciting developments in optical probe design
provide discriminatory power between related proteases. Despite
their concomitant release from degranulating neutrophils, the
various serprocidins perform distinct molecular functions (60).
Screening combinations of natural and unnatural amino acids
by their kinetic affinity and rate constants, Kasperkiewicz
et al. designed a HNE probe with a 100-fold sensitivity over
the previous champion substrate designed by Korkmaz et al.
(61). The group’s combinatorial substrate library technique
generated substrate-based activatable probes and inhibitory,
targeted probes and their approach included counter selection
which biases against the interference of substrate cleavage from
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FIGURE 1 | Structure of Craven’s neutrophil probe (A) before and (B) after cleavage by active HNE and indicating the resulting FAM fluorescence. (C) In a no-wash,
no-lyse whole blood flow cytometric assay, neutrophils activated with bacterial products take up Probe (8) and upregulate CD11b. Fluorescent signal is blocked in
activated neutrophils with 100µM sivelestat co-incubation. MFI = Geometric mean fluorescent index. *P < 0.05, **P < 0.01, exact multiplicity adjusted p values are
shown with the figure. (C) Reproduced under the CC BY 4.0 license (40).
similar protease families (62, 63). Finally, the recently synthesized
fluorogenic toolbox contained unique substrate-fluorophore
combinations for each of the four neutrophil serine proteases
(HNE, proteinase 3, cathepsin G and neutrophil serine protease
4) and revealed for the first time their uneven distributions in
azurophil granules (64).
To enable clinical, functional neutrophil imaging via HNE
activity at inflammatory sites a Neutrophil Activation Probe
(NAP) was developed (42). Using static quenching NAP’s
tribranched structure holds fluorescein moieties in close
proximity limiting fluorescence. Each of these SmartProbe’s three
branches contain an HNE substrate sequence cleaved by the
active enzyme to generate large fold increases in fluorescent
intensity. Encouraging results with NAP came from synthesizing
the SmartProbe to GMP standards and endomicroscopically
imaging neutrophil activation in ventilated and perfused ex vivo
human lungs (37). Craven et al. found NAP to be dequenched
within the phagolysosome specifically in response to NE and this
lead to a successful phase 1 clinical study (NCT01532024) (42).
The ability of NAP to inform clinical decisionmaking is currently
being investigated in the phase 2 clinical study, SNAP-IT
(number: NCT02804854). SNAP-IT will evaluate the utility of
imaging NAP-illumined neutrophils, endomicroscopically, in
intensive care unit patients.
Formyl Peptide Receptor 1
NIR imaging is often superior to other wavelengths as tissue
autofluorescence is lowest in this region of the visible spectrum.
Zhou et al. synthesized a NIR fMLF receptor 1 targeting
nanoprobe for imaging inflammation (Figure 3) (43). The issue
of inflammatory site access was solved by building the labeling
(cFLFLF) and fluorophore (Oyster-800) components onto a
hydrophilic 8-arm PEG scaffold. There are many benefits to
using the cFLFLF ligand: its high affinity FPR1 binding (Kd =
2 nM) generates a sensitive readout of leukocyte distribution
(65). The ability of cFLFLF probes to access inflammatory sites
with either PET (64Cu, 99mTc) or NIR (Cy5, Cy7) labels has also
been demonstrated. However FPR1 is not cell-type specific and
these probes bound macrophages (66) and neutrophils (67, 68).
cFLFLF probes may generate a useful readout when information
on inflammatory cell accumulation is sought in broad terms but
may fail to clarify whether clinical intervention should focus on
altering neutrophil or macrophage activity.
Pellico et al. created neutrophil-specific radiotracers with dual
PET and MRI signals by coating gallium-doped nanoparticles
with cFLFLF for FPR1 labeling (44). Coating with peptide can
produce significant probe hydrophobicity which has prevented
other radiotracers from reaching the inflammatory site. By
citrate-coating nanoparticles, the relatively large nanoparticle
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FIGURE 2 | Schematic representation of NE680 FAST before (A) and after (B) cleavage by active NE which alleviates fluorescence quenching. (C) Fluorescence
molecular tomography of NE680 FAST (4 nM intranasal) instilled into control, LPS/fMLP and LPS/fMLP mice treated with inhibitor. NIR signal is absent in untreated
controls and reduced in sivelestat (5 mg/kg intranasal) treated controls (D) and mean concentration of fluorescence (in nM) was quantified in the lung area ROIs (orange
cubes) for control (N = 12), LPS/fMLP (N = 16), and sivelestat (N = 12) groups. (C,D) Copyright 2011 Kossodo et al. Reproduced under the CC BY 3.0 license (41).
surface confers the necessary solubility for targeting neutrophils
in vivo. Although neutrophil depletion was capable of removing
signal, it also removes important cross-talk from the LPS
inflammatory response.
A truly neutrophil specific target has proved elusive. Instead
neutrophil specificity has arisen from combinatorial strategies
exploiting the unique confirmations of certain targets within
neutrophils. For example, HNE reaches such high concentrations
in neutrophils that most systems will fail to detect the minority
of HNE positive monocytes which bares far lower quantities of
the enzyme. Neutrophil specific functions can also be exploited
by careful probe design. Phagolysosome alkalinisation does
not occur in monocytes and enhance the fluorescence signal
of some fluorophores. The super-silent FRET probe combines
these structural and functional cellular characteristics to achieve
neutrophil specificity. Label-free methods of cell identification
have also sought neutrophils using targets found in other cell
types but uniquely arranged in neutrophils.
Label Free Neutrophil Imaging
Neutrophil imaging in the context of inflammatory research has
aimed at understanding the relevance of cellular components
to cell function. Questions of molecular colocalization and
characterization are well-served by fluorescent labels for
elucidating the spatiotemporal relationships of cells and
subcellular structures without altering the processes for
investigation. As translational research influences surgical
guidance questions of long-term cytotoxicity and ease-of-
adoption are more important. Label free imaging, which may
seem imprecise for research purposes, is often cheaper, safer and
does not require the considerable translation effort of alternative
techniques. Molecules such as NADH, elastin, and hemoglobin
have been claimed to provide intracellular and extracellular
autofluorescence, but signals from cells will always be an
amalgamation of signatures of multiple and complex analytes.
There is still much characterization to generate clinically
meaningful autofluorescence imaging and techniques such as
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FIGURE 3 | fMLF receptor targeting nanoprobes were implanted in control and neutrophil depleted mice, neutrophils were labeled and quantified. (A) Image of
hematoxylin and eosin staining and quantification of inflammatory cells. (B) Immunohistochemistry and quantification of neutrophils. (C) Fluorescence intensities over
4 h post-injection showing the diminished accumulation of the nanoprobe in neutrophil depleted mice compared to control. H&E, hematoxylin and eosin; IHC,
immunohistochemistry; PLA, poly(lactic acid); *P < 0.05, **P < 0.01. Copyright 2012 Zhou et al. Reproduced under the CC BY-NC 3.0 license (43).
fluorescence lifetime imaging may become an important source
of differentiation. Reflectance microscopy, which distinguishes
between matter of different refractive indices, is now also
capable of cellular resolution. For high-resolution imaging,
individual molecules can be detected and quantified via Raman
spectroscopy. Label free imaging is en route to becoming as
informative as fluorescence image-guided surgery can be, a limit
it may exceed in a multi-modal platform.
Raman Spectroscopy
By measuring the minute proportion of photons which
interact with molecules inelastically, Raman spectroscopy
can, non-destructively, describe the chemical composition
of unlabeled matter. The first look at a leukocyte using
Raman spectroscopy was when Puppels et al. compared
eosinophils and Chinese hamster lung cells (69). The group
found nuclei spectroscopically distinct from cytoplasm and
that distinctions between granulocytes may be made on the
basis of their cytoplasmic contents (70). In 1998, Otto et al.
collected the first Raman spectrum of activated neutrophils
(71). More recently, Ramoji et al. demonstrated the ability to
discern between lymphocytes and neutrophils with concomitant
Raman mapping of nuclear morphology (45). Using principal
components analysis, cells could be classified with 94% accuracy
in the validation dataset and predicted with 81% accuracy
in a new dataset from a completely different donor. As
Raman spectroscopy can describe intracellular contents it
may be better suited to quantifying cell function. Instead of
identifying cells, Harz et al. used spectrally distinct Raman and
fluorescence excitation wavelengths to successfully multiplex
these spectroscopic and microscopic techniques (2). Particularly
in such a multiplexed system, intracellular localization and
oxidation states of functionally significant molecules may be
revealed through Raman mapping to imitate whether or not
neutrophils are effecting processes such phagocytosis and to what
extent (72).
Two-Photon Endogenous FLIM
The question of whether or not technology as nascent
and complex as two-photon microscopy can be translated
into a clinical endomicroscopy technology is unanswered.
Although confocal endomicroscopy is in clinical use, two-
photon endomicroscopy (TPEM) carries additional fiber optics
challenges such as fiber non-linearity distorting the two-
photon excitation light and the low quantum yields of intrinsic
fluorophores (73). These and other hurdles were overcome
in 2008, when TPEM of human and mouse sarcomeres was
conducted using a GRIN lens (74). The technique involved
a minimally-invasive needle clad fiber capable of imaging
directly beneath the skin. In vivo TPEM was performed
laparoscopically with a “stick” lens which avoids GRIN lens
associated spherical aberrations revealing ovarian cancer through
a laparoscopic procedure, centimeters into the body (75).
However murine tissues were investigated in vivo with a flexible
FLIM endomicroscope, of working distance 135µm in 2011,
and the field continues to rapidly improve this label-free
technology (76).
Using two-photon excited fluorescence (TPEF), Zeng et al.
characterized blood cells by their endogenous fluorescence
lifetime signals (Figure 4). TPEF fluorescence lifetime imaging
can detect differences in bound and unbound NADH such
erythrocytes, agranulocytes and granulocytes are distinguishable
(46). As proportions of bound and free NADH vary by the
dominant metabolic pathway employed by the cell—TPEF
FLIM is functional imaging. Metabolic functional imaging may
be able to identify granulocytes undergoing phagocytosis but
whether or not phagocytosis and other factors affecting the
NAD/NADH ratio, such as oxygen availability, can be dis-
entangled remains unclear. By visualizing cytoplasmic protein,
TPEF FLIM can identify the size and shape of cells and,
by exclusion, their nuclei—detailing the characteristic lobular
structure of granulocyte nuclei. With neutrophils comprising
95% of the granulocytes population, these morphological
distinctions give TPEF FLIM neutrophil-specificity to rival the
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FIGURE 4 | TPEF showing granulocytes, agranulocytes with platelets (white arrows) and erythrocytes (a–c) under 600 nM excitation and (d–f) under 700 nM
excitation, with bright field images in (d) and (e) showing blood smears granulocytes and agranulocytes with platelets. Normalized spectra of blood cell
autofluorescence under 600 nm (5 mW) and 720 nm (10 mW) excitation, are seen in (g) and (h), respectively. The acquisition time for each TPEF image: 32 s;
resolution: 128 × 128 pixels; scale bar: 20µm; γ is the gamma value in the gamma correction of (e). Reproduced with permission from Zeng et al. Copyright 2013
SPIE (46).
best ligand-based, fluorescent probes. Although the distinction
between phagocytic and untreated neutrophils is subtle, this
technique can separate untreated from activated neutrophils
on morphological grounds. Quiescent neutrophils have a
rounded morphology but membrane ruﬄing characteristic
of neutrophil activation was visualized when neutrophils
phagocytosed E. coli (46).
MACROPHAGES AS BIOMARKERS
Macrophages are readily found at the site of inflammation or
infection, forming the first defense against pathogens. Although
they play a key role in the initiation of defensive inflammation,
recent literature suggests they are also responsible for the
resolution of inflammation and repair processes (77). Several
large studies show the role of macrophages in solid tumors,
sentinel lymph node metastasis, rheumatoid arthritis and liver
fibrosis (21–24). In ophthalmology, macrophages have been
shown to play a role in preventing ocular infection (78) and
contribute to corneal wound healing (79) and biomarkers of
macrophage activity have been linked to primary open angle
glaucoma and dry eye disease (80, 81).
Macrophages have been broadly classified into two different
phenotypes—M1 and M2, with further subsets M2a, M2b,
M2c identified, and they display plasticity by moving between
these phenotypes (82). Generally, the M1 “classically activated”
macrophages are seen as pro-inflammatory and exhibit killing
mechanisms against microorganisms, while M2 “alternatively
activated” macrophages are anti-inflammatory and exhibit
wound healing functions. Further evidence shows that they
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TABLE 3 | Overview of optical probes for imaging macrophages.
Target Molecule class Optical modality Models References
FR-β Small molecule SPECT/CT, in vivo imaging Mice/Human (RA) (85, 86)
CD206 Nanobody (sdAb) PET Mice (87)
Peptide Fluorescence Mice (88)
MMP-12 Peptidomimetic Fluorescence Mice (89)
Cathepsins Quenched polymer probe Fluorescence Rat (90)
Peptide—activity probe PET/CT and Fluorescence Mice, Human (PET in IPF patients) (91)
FIGURE 5 | Clinical uses of OTL38 showing whole body fluorescence imaging of a mouse bearing a FRα+ KB tumor in color (a) and grayscale (b,d) 2 h after
administering OTL38. Analysis of gray value vs. distance (c,e) [across the line from (b) or within the box from (d)]. Representative fluorescence images NSCLC and
ovarian cancer during image-guided surgery 2 h after administering OTL38. (f) Preoperative CT image of pulmonary tumor nodal, (g) overlay of fluorescence image
over white light image of pulmonary tumor nodal, and (h) immunohistochemical (IHC) staining of resected pulmonary tumor nodal indicating tumor is FRα+.
Representative fluorescence images over white light images of primary and metastatic ovarian tumors in (i) uterine adnexa and (j) uterus and bladder peritoneum. LT,
lung tumor; HL, healthy lung; FSF, Foerster sponge forceps; SF, surgeons fingers; C, cotton. Adapted with permission from Mahalingam et al. Copyright 2018
American Chemical Society (92).
do not rest in one polarization state, instead they may be
reactivated into a different state. The ability to understand
the crosstalk between macrophage activation signals and how
this alters their phenotypes would be valuable in characterizing
disease phenotypes. In oncology, tumor associated macrophages
(TAMs) represent a significant imaging target due to their
recruitment in the microenvironment of a tumor (83). Their
presence contributes to the invasiveness of tumors as they
have been linked to angiogenesis, cell proliferation, invasion
and immune suppression (84). Targets to visualize macrophages
includeMMP-12, cathepsin S, the macrophage mannose receptor
(CD206), and folate receptor beta (FR-β) (Table 3).
Folate Receptor Beta
Folate receptor (FR) targeting is a promising method for
visualization of cells that overexpress the folate receptor.
Recently, a demonstration of the capabilities of folate targeting
during fluorescence guided surgery of cancer was described
by Mahalingam (92). OTL-38 is an NIR labeled folate that
accumulates in cancer tissue, has a high target affinity and
enables the visualization of cancer tissue using image-guided
surgery (Figure 5). This agent has completed Phase I and II trials
for ovarian and lung cancers, and is now in Phase III clinical
trials for the detection of FR+ ovarian cancer (NCT03180307).
For inflammatory cells, the β isoform (FR-β) is expressed on
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FIGURE 6 | (A) Chemical structure of EC20—a folate radiolabel. (B) SPECT/CT images 99mTc-EC20 uptake in the lung of OVA-induced asthmatic mice, competition
experiment with 99mTc-EC20 plus 100-fold excess folate-glucosamine. Adapted with permission from Shen et al. Copyright 2013 American Chemical Society (86).
activated macrophages and has a high affinity for its ligand
folic acid (Kd = 10
−10 M) (93). Its identification on synovial
macrophages in patients with rheumatoid arthritis was first
described by Nakashima-Matsushita et al. (94). Studies on both
rheumatoid and osteoarthritis in dogs, horses, rats, mice, and
humans have demonstrated that essentially all joints experiencing
active inflammation uptake folate conjugates (93). A number
of studies have reported on the cellular uptake of FR targeted
molecules by activated monocytes (95) and macrophages in a
number of different diseases (85, 86, 96).
Xia et al. investigated the presence of the folate receptor on
activated macrophages from arthritic patients (85). Fluorescence
imaging was used to show that the folate receptor was a
valid marker for activated macrophages, while non-activated
macrophages did not express the folate receptor. After
characterizing that bacteria-recruited murine macrophages
expressed FR and that these were activated (upregulation of
Ly-6C/G, CD80, and CD86), folate-FITC was incubated with the
synovial fluid of patients with diagnosed rheumatoid arthritis.
A subset of the CD11b+ macrophages was found to uptake
folate-FITC, and competition experiments showed that this
uptake could be inhibited with the non-conjugated folic acid—
showing FR specificity. Finally, a technetium-radiolabelled folate
(FolateScan: EC20) was utilized to perform SPECT imaging of
human inflamed joints in a Phase II trial (NCT00588393).
In murine models of asthma, Shen et al. showed that ex
vivo lung macrophages with an M2 phenotype (arginase+,
CD206+) bound the green fluorescent probe, folate-Oregon
Green. Further, SPECT/CT imaging of 99mTc-EC20 showed
uptake in ovalbumin induced asthmatic lungs, while there was
no uptake in the lungs of healthy mice (Figure 6) (86).
Recent work by Poh et al. showed that a folate liposome
could act as a specific method of targeting FR+ immune
cells, specifically in mouse models of colitis and atherosclerosis
(97). This study used fluorescent DiD liposomes, labeled with
folate, as a demonstration of the ability to deliver payloads via
the folate receptor which can accumulate in inflamed tissues.
Atherosclerotic mice (ApoE−/− mice fed a high fat diet) were
injected via the tail vein with 2 mg/kg of NT-liposome-DiD or
Fol-liposome-DiD, respectively. Fluorescence imaging showed
selective uptake of Fol-liposomes in the atherosclerotic mice.
To further our understanding of the clinical applicability
of folate targeted imaging agents, the field should aim to
evaluate their performance in human inflammatory models. It
is however also worth mentioning an observation from this
field; the use of folate depleted media is necessary for any folate
targeting cell studies due to high levels of folic acid in routine
media formulations.
CD206
CD206, also known as the macrophage mannose receptor
(MMR), is a well-reported marker of M2 differentiated
macrophages (82). Its functional role is to recognize mannose
lectins found on pathogens. A number of different approaches
to probe design have been taken against CD206+ macrophages,
from antibodies to a more recent report of a target-binding
peptide. The Manocept concept of nanomolecule imaging agents
targeting the lectin domain of CD206 has resulted in the FDA
approval of γ-Tilmanocept, a 99mTc-labeled radiolabelled tracer
for the imaging of sentinel lymph nodes (98). A similar strategy
was applied by Kim et al. who developed a near-infrared MMR
targeting polymer and utilized using OCT-NIRF imaging to
visualize carotid atheroma plaques (99). However, mannose
derivatives are not specific to CD206 and can be recognized by
other mannose receptors (100). Therefore, there is a need to
develop ligands that are more specific for CD206 which are more
suitable for use in the clinic.
Targeted Nanobodies
The most advanced agents for CD206 targeting are labeled
nanobodies, which have shown promise as molecular imaging
agents (101). Nanobodies (Nb) have been developed as imaging
tracers against a number of targets in oncology and inflammation
due to their high affinities and small size compared to
antibodies (102). Movahedi et al. produced a 99mTc-labeled
nanobody against MMR with an affinity of 2 nM determined
by SPR and validated its use for SPECT/micro-CT imaging
of tumor-associated macrophages in preclinical models (103).
SPECT/CT imaging in tumor-bearing mice showed uptake of
the Nb which was significantly higher than uptake of the
control Nb with analysis of the dissected tissue confirming
these findings.
This nanobody was further developed by Blykers et al.
as an 18F-PET tracer for the detection of macrophages in
tumor stroma (87). Tumor associated macrophages (TAMs)
with upregulated CD206 were found to be tumor promoting.
In vitro studies with the 18F-fluorobenzoic acid (FB) labeled
nanobody (anti-MMR 3.49) showed that it had a high affinity
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for human MMR (KD = 1.8 nM), while in vivo biodistribution
studies showed fast renal clearance and specific retention in
the tumor and MMR-expressing tissue. In a small animal PET
imaging study, the nanobody was specifically recognized by
MMR in 3LL-R tumor bearing mice, when compared with
FIGURE 7 | Transverse and coronal PET/CT images of WT (left) vs.
MMR-deficient (right) 3LL-R tumor–bearing mice scanned 3 h after injection of
18F-FB-anti MMR 3.49. Arrows point to tumor (T), kidney (K), and bladder (B).
Adapted with permission from Blykers et al. Copyright 2015 SNMMI (87).
the uptake in MMR-deficient mice (Figure 7). This ligand
shows promise as a radiopharmaceutical, while in future
it could be developed as an optical probe for highlighting
M2 macrophages by fluorescence guided surgery. As noted
by Debie et al., the fluorophore chosen and method of
conjugation should be carefully considered when developing
labeled nanobodies (104).
Peptides
Fluorescent peptides are a widely utilized method for labeling
receptors and a number of peptidic agents are under clinical
investigation for cancer and bacterial infection imaging (10).
Recently, Scodeller et al. showed that M2-like TAMs could
be targeted by a “FAM-UNO” fluorescent peptide [sequence:
5(6)-FAM-Ahx-CSPGAKVRC] (88). The peptide sequence was
identified by in vivo phage display of peptides that bound
peritoneal macrophages in 4T1 tumor-bearing mice. FAM-UNO
was found to target M2-like TAMs via the CD206 receptor
(Figure 8) and this binding was confirmed by fluorescence
anisotropy. Cargos were delivered to TAMs by coating polymer
vesicles with the FAM-UNO peptide and these could be
used as a contrast agent for sentinel lymph node imaging.
Although this agent is yet to be translated to humans, it
could be an attractive method for imaging TAMs. However,
green autofluorescence of human tissues means alternative
fluorophores may need to be considered to make a case for future
clinical applications.
MMP-12
The matrix metalloproteinases (MMPs) are a family of proteases
that play a key role in ECM structure, function and remodeling.
In the tumor microenvironment macrophages have been found
to be potent producers of MMP 2 and 9 (105). It is
important to note the pioneering work of the Tsien lab and
Avelas Biosciences in advancing activatable cell penetrating
peptides (ACPPs) for imaging protease activity. In 2004,
the lab demonstrated that an MMP-2 cleavable ACPP could
detect tumor cells in resected tissue (106). More recently,
Miampamba et al. developed AVB-620, a ratiometric ACPP
FIGURE 8 | FAM-UNO accumulates in CD206+, TIE2+ macrophages in breast tumors (a,b) and lymph nodes (c). 4T1 tumor bearing mice were injected i.v. with
FAM-UNO (30 nmol), mice were sacrificed after 2 h and tumor tissues were analyzed by immunofluorescence: rabbit anti-FAM (green), rat anti-CD206 (red) antibodies
and counterstained with DAPI. Scale: 100µm. Reproduced under the CC BY 4.0 license (88).
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FIGURE 9 | Left: Structure of the Cy3-labeled MMP-12 probe 2. Right: Immunostaining demonstrating that the Cy3-labeled probe 2 (red) binds to carotid arteries and
co-localizes with an MMP-12 antibody (A, green) and F4/80 positive cells (B, green). Nuclei are stained with DAPI (blue). Scale: 50µm. Reproduced under the CC BY
4.0 license (89).
with Cy5 and Cy7 fluorophores that is a substrate for MMP-
2 and -9 (107). This agent has completed Phase I clinical
trials for imaging breast cancer tumors in patients undergoing
surgery (NCT02391194).
While there aremany non-selective imaging agents forMMPs,
there is a lack of selective MMP tracers and this may hamper
the understanding of the role of a specific MMP in disease.
For example MMP-12, macrophage elastase, is responsible for
the breakdown of elastin and it is associated with a number of
inflammatory pathologies such as aortic aneurysm, emphysema,
and rheumatoid arthritis (108). It has been characterized as
having a protective role during wound healing in injury
models (109).
Bordenave et al. reported the synthesis and evaluation of
a Cy5 MMP-12 probe based on a pseudopeptide (RXP470.1)
which had previously been shown to inhibit atherosclerotic
plaque growth in vivo (110). This study noted that the
fluorophore used was important to the blood clearance rate and
biodistribution of this probe, a factor that has been highlighted
by other groups working on the development of fluorescent
probes. Further optimization lead to a zwitterionic labeled
probe which had good affinity to MMP-12 and fast blood
clearance (89). The selectivity of this MMP inhibitor should
give advantages over other pan-MMP probes in showing the
specific MMP implicated in a disease. Immunostaining showed
an analog (probe 2) bound to MMP-12+ and F4/80 macrophages
(Figure 9). The probe was used for imaging active forms of
MMP-12 in murine models. Using a sponge implantation model
of sterile inflammation, increased cell infiltration was seen
which correlated with mannose receptor positive macrophages.
The study was also interested in the role that MMP-12 plays
in aneurysm. In a model of carotid aneurysm, significant
upregulation of MMP-12 was seen, along with significantly
higher signal for the probe, compared to the control (Figure 9).
Although this was only demonstrated in a mouse model, because
of this probe’s high selectivity and the clinical relevance of the
experimental setup could allow this probe to be used in an
intraoperative setting.
Cathepsins
TAMs remodel the extracellular matrix (ECM) through MMPs
and cathepsins, specifically during tumor invasion (111). Onda
et al. used a commercial NIR fluorescent protease-activatable
probe (ProSense), in which they demonstrated imaging of
cathepsin activity and confirmed its localization to macrophages.
Using in vivo and ex vivomodels of colon cancer they showed that
infiltrating TAMs initiate tissue remodeling at the tumor margins
by secreting cathepsins. ProSense signal at the tumor margin was
shown to be due to cathepsin B+ macrophage infiltration in a rat
colon model (90). However, large probes such as ProSense suffer
from slow tumor uptake leading to slow rates of activation, as well
as demonstrating off-target activation by other proteases which
limits their applicability as a fluorescence diagnostic tool.
A number of alternative cathepsin activatable probes are
under development (112, 113). Withana et al. investigated the
role that macrophages play in idiopathic pulmonary fibrosis
(IPF) by staining human biopsy tissue from IPF patients. The
optical probe BMV109 is broadly activated by cathepsins B, S, L,
and X, was used to validate pan-cathepsin labeling of sectioned
frozen tissue. This showed that macrophages expressing active
cathepsins were at fibrotic sites in comparison to healthy tissue
which showed no cathepsin activity (91). To date, this probe
has only been demonstrated in the topical labeling of IPF tissue,
further investigation would be necessary to show its utility in
fluorescence based diagnostics in the clinic.
CONCLUSION
The nascent field of optical molecular imaging of inflammatory
cells appears to be a vibrantly innovative arena full of
early-stage biomarkers that offer promise of patient benefits.
Targeting neutrophils and macrophages may deliver previously
inaccessible measures of disease activity across common and life-
threatening diseases. Whilst, in this review, the current stage
of neutrophil and macrophage imaging has been discussed,
clearly other inflammatory cells such as T cells play major role
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in interventional medicine. With many non-redundant targets
and readouts available, probe multiplexing seems a particular
advantage of this field with the potential to matching monitoring
and treatment with immunological precision. As well as being
informative in its own right, parallel label-free imaging may
become a rapid means of interpreting labeled techniques across
multiple contexts and machine learning data-reduction stands to
push the power of OMI even further. An exciting therapeutic
potential lies in the how imaging agents can impact the drug
discovery process—with immune cells. These new technologies
stand to enrich assay outputs, accelerate drug development
decisions and clinical outputs, and enable better direct drug
response metrics in trials.
Future studies will demonstrate the translatability of imaging
agents into clinically useful optical probes. Despite the plethora
of novel reagents advancing with in vitro investigations
very few have begun the translational journey. This inertia
is perhaps not surprising as the technical demands of
translating novel imaging methods can become overwhelming,
especially within an academic environment. Probes must be
innovative enough to meet clinical needs, yet synthetically
feasible and complementary to imaging systems. This is a
fiercely interdisciplinary pursuit from start to finish and
nearly impossible without optical imaging device standards,
as all technologies must meet safety and efficacy standards.
Without standardization, investigators risk underestimating
translation-ready reagents with “sub-standard” apparatus, or
unnecessarily pursue doomed reagents with poor selectivity and
specificity (114).
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